GLP-1 Daily: Ozempic & Wegovy News
Wegovy Liver-Fat Data at EASD 2026, and What the Wegovy Pill Changes
Monday, October 12, 2026 · 4 min
Novo Nordisk's post hoc STEP UP analysis at EASD 2026 says Wegovy brought liver fat below 5 percent in 23 of 26 adults with obesity. We weigh that small, company-presented result and what the oral Wegovy pill does and doesn't change for patients.
Listen
Show notes
Novo Nordisk's post hoc STEP UP analysis at EASD 2026 says Wegovy brought liver fat below 5 percent in 23 of 26 adults with obesity. We weigh that small, company-presented result and what the oral Wegovy pill does and doesn't change for patients.
In this episode
- Wegovy reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat at EASD2026 - Novo - Medical Update Online — Medical Update Online
“Novo Nordisk presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes. Change in percentage of liver fat, determined by…”
- Step Back — Now that the FDA has approved an oral version of Wegovy, what actually changes for patients compared with the weekly injection—and what still depends on insurance coverage, prescribing decisions, and longer-term evidence?
Background sources
- FDA approves Wegovy weight loss pill from Novo Nordisk — Berkeley Lovelace Jr.
- US regulators approve Wegovy pill for weight loss — Associated Press
- Wegovy Weight-Loss Pills Hit U.S. Pharmacies—Costs and Treatments Explained | Scientific American — Lauren J. Young
- What to Know About the New Wegovy Pill | U.S. News — Claire Wolters, Rachael Hood
- Novo's Wegovy pill improves weight loss after switch from injections — Annika Kim Constantino
- Wegovy Pill: What to Know About Oral Wegovy for Weight Loss | Ro — Amelia Willson